Azurity Pharmaceuticals entered into a definitive agreement to acquire Arbor Pharmaceuticals from existing investors, including JW Asset Management and KKR.
Azurity Pharmaceuticals was born as a corporate identity in June 2019 with the acquisition of Silvergate Pharmaceuticals by CutisPharma.
NovaQuest Capital Management, which supported CutisPharma and its management team in the transaction, became the majority owner of the new entity, which focused on developing drug delivery technologies to provide customized dosage forms to patients. The value of that transaction was not disclosed, but it was backed by NovaQuest Fund I, which held its final close . . .
Unlock this article instantly, along with the rest of our premium content and benefits including daily/weekly/monthly newsletters.
A pay-as-you-go plan to get you started
→ Instantly unlock all new and archived articles
→ Daily, weekly and monthly e-mail newsletters
→ Access to the weekly AW Deal Watch by AW Research
Get more for less - 20% discount over monthly
→ Everything in Monthly PLUS:
→ Access to articles and data from AW Research
→ AW Annual Investor Compendium – our comprehensive guide to investor activity, with a ranking of the most active investors for the year and profiles of the top global allocators